Cell labelling for in vivo use and in process quality control

Altrika、爱丁堡大学化学学院、Roslin Cellab和Barts以及The伦敦的联盟将研发、制造、临床和商业化经验带到了体外和体内追踪临床相关细胞群的挑战中。缺乏体内跟踪方法导致研发、制造和临床限制、宝贵的研究人员时间和细胞产量损失以及相关成本。该项目采用了一种创新的无毒细胞标签，该标签稳定，具有成本效益且易于检测。它将证明适用于一系列未满足临床需求的再生医学疗法，以及提高研发活动和制造过程的效率，并提高临床交付的功效。鉴于再生医学的发展，该平台可以在2020年将行业成本降低2.75亿美元。

The consortium of Altrika, the University of Edinburgh’s School of Chemistry, Roslin Cellab and Barts and The London bring R&D, manufacturing, clinical and commercialisation experience to the challenge of tracking clinically relevant cell populations in vitro and in vivo. The absence of an in vivo tracking methodology leads to R&D, manufacturing and clinical constraints, valuable researcher time and cell yield losses, and associated costs. This project utilises an innovative, non-toxic cell label that is stable, cost-effective and easy to detect. It will demonstrate applicability to a range of regenerative medicine therapies for unmet clinical needs, as well as increasing the efficiency of R&D activities and manufacturing processes, and improving the efficacy of clinical delivery. Given the growth of regenerative medicine, this platform could reduce industry costs by as much as $275m in 2020.